SCHEMBL3365040

SCHEMBL3365040

C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1c1c[nH]c2c(=O)[nH]c(N)nc12

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PNP P00491 13/20 0.54
HPRT1 P00492 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365046 1.00 PNP (0.54) PNPHPRT1
SCHEMBL13847106 0.87 PNP (0.53) PNPHPRT1
SCHEMBL3299956 0.81 PNP (0.52) PNP
SCHEMBL3299946 0.81 PNP (0.52) PNP
SCHEMBL3300370 0.81 PNP (0.39) PNP
SCHEMBL264086 0.81 PNP (0.39) PNP
SCHEMBL6938475 0.81 ADORA2A (0.49) PNP
SCHEMBL3301755 0.80 PNP (0.40) PNP
SCHEMBL3301763 0.80 PNP (0.40) PNP
SCHEMBL3990229 0.80 PNP (0.39) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344132-B2 Methods for the preparation of 9-deazapurine derivatives BioCryst Pharmaceticals, Inc. (US) 2013-01-01 US claimed
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES BIO CRYST PHARMACEUTICALS , INC. (US) 2010-04-15 US claimed
US-20080021047-A1 C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase MERCK SHARP & DOHME LLC 2008-01-24 US claimed
US-8344132-B2 Methods for the preparation of 9-deazapurine derivatives BioCryst Pharmaceticals, Inc. (US) 2013-01-01 US disclosed
US-8344132-B2 Methods for the preparation of 9-deazapurine derivatives BioCryst Pharmaceticals, Inc. (US) 2013-01-01 US disclosed
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES BIO CRYST PHARMACEUTICALS , INC. (US) 2010-04-15 US disclosed
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES BIO CRYST PHARMACEUTICALS , INC. (US) 2010-04-15 US disclosed
US-7534767-B2 C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2009-05-19 US disclosed
US-7534767-B2 C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2009-05-19 US disclosed
US-20080021047-A1 C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase MERCK SHARP & DOHME LLC 2008-01-24 US disclosed
US-20080021047-A1 C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase MERCK SHARP & DOHME LLC 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES DPYD, TYMP, UNG PNP 8/4885HPRT1 13/4885
US-20080021047-A1 C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase NSUN2, PNP, RNGTT PNP 2/4885HPRT1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.